Análisis de la acción China Pharma Holdings Inc (CPHI)

Análisis de IA of China Pharma Holdings Inc (CPHI)

Vender

Given the current price of $0.61 and an RSI of 29.837, which indicates the stock is oversold, it may seem like a buying opportunity. However, the stock has a staggering year-to-date change of -49.89% and a 1-year change of -60.98%, reflecting severe downward momentum. Furthermore, the gross margin is currently at 8.81%, which is low compared to industry standards, and the forward P/E ratio is 1.5581, suggesting potential undervaluation but also highlighting the risk of continued losses. The main risk is the high net income loss of $1,458,123 in Q2 2026, indicating ongoing financial struggles. Therefore, while there are indicators that could suggest a future rebound, the current financial health and performance metrics do not support a buy recommendation at this time.

Métricas de valoración

El PER previsto actual de China Pharma Holdings Inc (CPHI) es 1.56, frente a su media de 5 años de 0.26.

PER previsto

Muy sobrevalorado

Media 5A P/E

0.26

P/E actual

1.56

Sobrevalorada

0.83

Infravalorada

-0.32

EV/EBITDA previsto

Valor razonable

Media 5A EV/EBITDA

33.64

EV/EBITDA actual

-0.18

Sobrevalorada

269.99

Infravalorada

-202.72

Precio/ventas previsto

Sobrevalorado

Media 5A P/S

0.04

P/S actual

0.23

Sobrevalorada

0.19

Infravalorada

-0.10

Escenarios de precio de Alphio AI para CPHI

Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.

A

Alcista

Alcista · 25%CPHI

$2.26

Precio del escenario

B

Base

Base · 50%CPHI

$2.13

Precio del escenario

B

Bajista

Bajista · 25%CPHI

$2.05

Precio del escenario

Preguntas frecuentes sobre CPHI, respondidas por Alphio AI

China Pharma Holdings Inc is a company principally engaged in the development, manufacture, and marketing of pharmaceutical products for human use. The Company is mainly engaged in the development, manufacture, and marketing of pharmaceutical products for high-incidence and high-mortality diseases and medical conditions prevalent in the PRC. The Company's products include dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. The Company's products and solutions are mainly applied in the treatment of various diseases and medical conditions. The Company mainly operates in the domestic market. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Given the current price of $0.61 and an RSI of 29.837, which indicates the stock is oversold, it may seem like a buying opportunity. However, the stock has a staggering year-to-date change of -49.89% and a 1-year change of -60.98%, reflecting severe downward momentum. Furthermore, the gross margin is currently at 8.81%, which is low compared to industry standards, and the forward P/E ratio is 1.5581, suggesting potential undervaluation but also highlighting the risk of continued losses. The main risk is the high net income loss of $1,458,123 in Q2 2026, indicating ongoing financial struggles. Therefore, while there are indicators that could suggest a future rebound, the current financial health and performance metrics do not support a buy recommendation at this time.